Related coverage linked through entity extraction aliases.
May 11, 2026
Sino Biopharmaceutical won Chinese approval for a new indication for benmelstobart as maintenance therapy in unresectable stage III NSCLC after chemoradiotherapy. Phase III R-ALPS data showed significantly prolonged progression-free survival versus placebo and a manageable safety profile.
Apr 20, 2026
Phase III data showed dirozalkib improved progression-free survival and intracranial efficacy versus crizotinib in first-line ALK-positive advanced NSCLC. The drug received NMPA approval in August 2025.
Feb 16, 2026
Eli Lilly's Retevmo (selpercatinib) demonstrated statistically significant event-free survival improvement in the Phase III LIBRETTO-432 trial for early-stage RET fusion-positive non-small cell lung cancer.
Feb 16, 2026
Eli Lilly announced positive Phase 3 LIBRETTO-432 trial results showing Retevmo (selpercatinib) significantly improved event-free survival in patients with early-stage RET fusion-positive non-small cell lung cancer as adjuvant therapy.
Feb 15, 2026
Nuvalent provided updates on regulatory milestones for its lead oncology programs, including FDA acceptance of the zidesamtinib NDA with a September PDUFA date and plans to submit an NVL-655 NDA in the first half of 2026.
